X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
KT-621 is a once daily, oral STAT6 degrader with a potential biologics-like efficacy profile, to address multiple diseases including atopic dermatitis, asthma, and chronic obstructive pulmonary disorder, among others.
Lead Product(s): KT-621
Therapeutic Area: Dermatology Product Name: KT-621
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2024
Details:
Kymera will use the proceeds to advance its pipeline of preclinical and clinical degrader programs, including SAR444656 (KT-474), a first-in-class IRAK4 degrader, for the treatment of immune-inflammatory diseases, such as hidradenitis suppurativa, atopic dermatitis.
Lead Product(s): KT-474
Therapeutic Area: Dermatology Product Name: SAR444656
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $275.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 09, 2024
Details:
Kymera will use the proceeds to advance its pipeline of preclinical and clinical degrader programs, including SAR444656 (KT-474), a first-in-class IRAK4 degrader, for the treatment of immune-inflammatory diseases, such as hidradenitis suppurativa, atopic dermatitis.
Lead Product(s): KT-474
Therapeutic Area: Dermatology Product Name: SAR444656
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $275.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 05, 2024
Details:
Kymera will use the proceeds to advance its pipeline of preclinical and clinical degrader programs, including SAR444656 (KT-474), a first-in-class IRAK4 degrader, for the treatment of immune-inflammatory diseases, such as hidradenitis suppurativa, atopic dermatitis.
Lead Product(s): KT-474
Therapeutic Area: Dermatology Product Name: SAR444656
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $287.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 04, 2024
Details:
Under the collaboration, Kymera is evaluating KT-474 (SAR444656), a first-in-class, investigational IRAK4 degrader, in the randomized Phase 2 clinical trial for Atopic Dermatitis.
Lead Product(s): SAR444656
Therapeutic Area: Dermatology Product Name: KT-474
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $2,150.0 million Upfront Cash: $150.0 million
Deal Type: Collaboration December 07, 2023
Details:
Under the collaboration, Kymera is evaluating KT-474 (SAR444656), a first-in-class, investigational IRAK4 degrader, in the randomized Phase 2 clinical trial in hidradenitis suppurativa.
Lead Product(s): SAR444656
Therapeutic Area: Dermatology Product Name: KT-474
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $2,150.0 million Upfront Cash: $150.0 million
Deal Type: Collaboration October 27, 2023
Details:
KT-333 is a highly selective degrader of STAT3 in development for the treatment of multiple STAT3-dependent pathologies, including hematological malignancies and solid tumors.
Lead Product(s): KT-333
Therapeutic Area: Oncology Product Name: KT-333
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
KT-253 is a novel, highly potent and selective heterobifunctional MDM2 degrader, has superior activity compared to MDM2 SMIs and demonstrated greater than 200-fold improvements in both in vitro oncologic cell growth inhibition and apoptosis.
Lead Product(s): KT-253
Therapeutic Area: Oncology Product Name: KT-253
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2023
Details:
The expanded partnership comprises 12 targets and grants Kymera exclusive rights to compounds discovered within the collaboration. X-Chem will apply its world-leading DEL platform to support Kymera’s discovery of small molecules and best-in-class protein degraders.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Recipient: X-Chem
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 31, 2023
Details:
In patients with HS and AD, KT-474 demonstrated plasma PK in Part C that was comparable to healthy volunteers in MAD3. Initial Phase 2 clinical trial of KT-474 will investigate its potential in HS and AD with the first study initiating in 2023.
Lead Product(s): KT-474
Therapeutic Area: Dermatology Product Name: KT-474
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
